Elicio Therapeutics
ELTX
48 hedge funds and large institutions have $15.3M invested in Elicio Therapeutics in 2026 Q2 according to their latest regulatory filings, with 24 funds opening new positions, 14 increasing their positions, 3 reducing their positions, and 23 closing their positions.
367% more repeat investments, than reductions
Existing positions increased: 14 | Existing positions reduced: 3
118% more call options, than puts
Call options by funds: $5.94M | Put options by funds: $2.72M
6.19% more ownership
Funds ownership: 14.35% → 20.54% (+6.2%)
2% more funds holding
Funds holding: 47 → 48 (+1)
4% more first-time investments, than exits
New positions opened: 24 | Existing positions closed: 23
46% less capital invested
Capital invested by funds: $28.2M → $15.3M (-$12.9M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
+$7.18M |
| 2 |
KCM
Knoll Capital Management
Miami,
Florida
|
+$5.83M |
| 3 |
Geode Capital Management
Boston,
Massachusetts
|
+$1.77M |
| 4 |
State Street
Boston,
Massachusetts
|
+$1.29M |
| 5 |
IC
Ikarian Capital
Dallas,
Texas
|
+$1M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Balyasny Asset Management
Chicago,
Illinois
|
-$2.62M |
| 2 |
Renaissance Technologies
New York
|
-$1.3M |
| 3 |
Millennium Management
New York
|
-$992K |
| 4 |
Marshall Wace
London,
United Kingdom
|
-$797K |
| 5 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$711K |
ELTX Hedge Fund Activity: Q2 2026 in Review
48 of the 8,318 institutional investors tracked by Wall St. Rank reported a position in Elicio Therapeutics (ELTX) for Q2 2026, worth a combined $15.3M — down 46% from $28.2M a quarter earlier.
Buyers outnumbered sellers: 24 funds opened new ELTX positions and 23 closed out — a net gain of 1 holder — while 14 added to existing stakes and 3 trimmed.
The largest buyer was BlackRock, adding an estimated $7.18M. The largest seller was Balyasny Asset Management, exiting entirely with an estimated $2.62M sold.
- 48 institutional investors held Elicio Therapeutics (ELTX) as of Q2 2026, up from 47 in Q1 2026.
- Funds reported $15.3M of Elicio Therapeutics stock for Q2 2026, down 46% quarter-over-quarter.
- 24 funds opened new Elicio Therapeutics positions in Q2 2026 and 23 closed out, a net change of +1 holder.
- The largest Elicio Therapeutics buyer in Q2 2026 was BlackRock, an estimated $7.18M added.
- The largest Elicio Therapeutics seller in Q2 2026 was Balyasny Asset Management, an estimated $2.62M sold.
Based on aggregated 13F filings for Q2 2026.